These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 9398823)

  • 1. Olopatadine for allergic conjunctivitis.
    Med Lett Drugs Ther; 1997 Nov; 39(1014):108-9. PubMed ID: 9398823
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and artificial tears in seasonal allergic conjunctivitis.
    Kamis U; Ozturk BT; Ozkagnici A; Gunduz K
    Acta Ophthalmol Scand; 2006 Feb; 84(1):148-9. PubMed ID: 16445458
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
    Brodsky M; Berger WE; Butrus S; Epstein AB; Irkec M
    Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis.
    Abelson MB; Gomes PJ; Vogelson CT; Pasquine TA; Turner FD; Wells DT; Robertson SM
    Curr Med Res Opin; 2005 May; 21(5):683-91. PubMed ID: 15969867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-seasonal treatment with topical olopatadine suppresses the clinical symptoms of seasonal allergic conjunctivitis.
    Shimura M; Yasuda K; Miyazawa A; Otani T; Nakazawa T
    Am J Ophthalmol; 2011 Apr; 151(4):697-702.e2. PubMed ID: 21257151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB; Greiner JV
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis.
    Yaylali V; Demirlenk I; Tatlipinar S; Ozbay D; Esme A; Yildirim C; Ozden S
    Acta Ophthalmol Scand; 2003 Aug; 81(4):378-82. PubMed ID: 12859265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge.
    Abelson MB; Spangler DL; Epstein AB; Mah FS; Crampton HJ
    Curr Eye Res; 2007 Dec; 32(12):1017-22. PubMed ID: 18085465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate.
    Aguilar AJ
    Acta Ophthalmol Scand Suppl; 2000; (230):52-5. PubMed ID: 11057352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Opatanol].
    Johansen S
    Ugeskr Laeger; 2003 Jul; 165(30):2957. PubMed ID: 12926197
    [No Abstract]   [Full Text] [Related]  

  • 12. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%.
    Artal MN; Luna JD; Discepola M
    Acta Ophthalmol Scand Suppl; 2000; (230):64-5. PubMed ID: 11057355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [First Hungarian report of olopatadine eyedrop therapy in children and adults suffering from seasonal allergic conjunctivitis].
    Endre L; Hidasi V
    Orv Hetil; 2006 Sep; 147(36):1741-3. PubMed ID: 17087018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Olopatadine].
    Taéron C
    Rev Infirm; 2004 Apr; (100):43-4. PubMed ID: 15222186
    [No Abstract]   [Full Text] [Related]  

  • 15. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
    Leonardi A; Quintieri L
    Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.
    Vogelson CT; Abelson MB; Pasquine T; Stephens DM; Gamache DA; Gross RD; Robertson SM; Yanni JM
    Allergy Asthma Proc; 2004; 25(1):69-75. PubMed ID: 15055565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial.
    Avunduk AM; Tekelioglu Y; Turk A; Akyol N
    Clin Ther; 2005 Sep; 27(9):1392-402. PubMed ID: 16291412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergic conjunctivitis and contact lenses: experience with olopatadine hydrochloride 0.1% therapy.
    Brodsky M
    Acta Ophthalmol Scand Suppl; 2000; (230):56-9. PubMed ID: 11057353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
    Rosenwasser LJ; O'Brien T; Weyne J
    Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model.
    Abelson MB; Welch DL
    Acta Ophthalmol Scand Suppl; 2000; (230):60-3. PubMed ID: 11057354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.